Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Early outcomes with a standardized admission order set for sickle cell crisis: A real-world single-institution retrospective review

Deevyashali Parekh, Osama Batayneh, Ansy Patel et al. Nov 03, 2025 pp. 6528-6528 10.1182/blood-2025-6528

Abstract Introduction: Sickle cell disease (SCD) is an inherited disorder affecting the beta-globin gene encoding the be...

Next-generation sequencing panel for hereditary erythrocytosis identifies genomic variants in over half of adults with otherwise unexplained erythrocytosis

Mahsa Rezasoltani, Jennifer Herrick, Aruna Rangan et al. Nov 03, 2025 pp. 2877-2877 10.1182/blood-2025-2877

Abstract Background: JAK2-unmutated erythrocytosis constitutes a spectrum of hereditary and acquired entities. We assessed the diagnostic yi...

Mitochondrial hyperactivity predicts chemotherapy relapse and venetoclax resistance in pediatric B-cell acute lymphoblastic leukemia

Jingliao Zhang, Peng Wu, Yongjuan Duan et al. Nov 03, 2025 pp. 3361-3361 10.1182/blood-2025-3361

Abstract Background: Relapse remains the major cause of treatment failure and mortality in pediatric B-cell acute lymphoblastic leukemia (B-A...

Outcomes of myeloablative vs reduced and non-myeloablative conditioning in MRD-negative AML and ALL with ptcy-based GVHD prophylaxis

Sarah Sulkowski, Lily Zekavat, Joanne Filicko-O'Hara et al. Nov 03, 2025 pp. 7716-7716 10.1182/blood-2025-7716

Abstract Introduction: The optimal conditioning intensity for patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (A...

Survival outcomes of multiple myeloma patients previously exposed to BCMA-targeted therapies in the honeur european network

Roman Hajek, Jiri Minarik, Stork Martin et al. Nov 03, 2025 pp. 4581-4581 10.1182/blood-2025-4581

Abstract Introduction: Survival rates for patients with multiple myeloma (MM) have recently improved, thanks to an increase in treatment opt...

Contextualising and tailoring standards-based audit (SBA) processes for sickle cell disease (SCD) care in Zambia: A pilot Study

Mmamulatelo Siame-Mumba, Imelda Bates, Wesam Mansour et al. Nov 03, 2025 pp. 7895-7895 10.1182/blood-2025-7895

Abstract Background Sickle Cell Disease (SCD) is the most common inherited haemoglobinopathy in the world, affecting mostly Sub-Saharan Afri...

Identification and functional characterization of a novel best-in-class anti-CD79b CAR T cell immunotherapy using a multidimensional screening strategy

Jean Lemoine, Guido Ghilardi, Yong Lee et al. Nov 03, 2025 pp. 5905-5905 10.1182/blood-2025-5905

Abstract Introduction: Chimeric antigen receptor T cell therapy targeting CD19 (CART19) has revolutionized the treatment of large B cell lym...

Trends in collecting health-related quality-of-life measures among hematology gene therapy clinical trials

Hae Lin Cho, Alice Levinger, Yu Jun Li et al. Nov 03, 2025 pp. 6157-6157 10.1182/blood-2025-6157

Abstract Background: Health-related quality-of-life (HRQOL) is increasingly recognized as a key, patient-centered clinic...

Safety of myeloablative total marrow and lymphoid irradiation versus chemotherapy-based conditioning in adults with high-risk acute lymphoblastic leukemia in a limited resources setting

Alexia E. Gonzalez-Lozano, Gerardo Garcia-Salas, Miguel Campos et al. Nov 03, 2025 pp. 5998-5998 10.1182/blood-2025-5998

Abstract Introduction In patients with relapsed or refractory acute lymphoblastic leukemia (RR ALL), allogeneic hematopo...

Maintaining higher hemoglobin levels is associated with improved overall survival in Myelodysplastic Syndromes (MDS): A real-world retrospective analysis of electronic health records from a US community setting over the past 20 years

Zhaohui Su, Matthew Whitesell, Lisa Herms et al. Nov 03, 2025 pp. 2095-2095 10.1182/blood-2025-2095

Abstract BACKGROUND Anemia with chronic ineffective erythropoiesis is the most common cytopenia in MDS and often require...

Impact of G-CSF in AML patients treated with venetoclax and azacitidine: A dataml registry study

Léopoldine Lapierre, Lucie Laemmel, Emilie Berard et al. Nov 03, 2025 pp. 3445-3445 10.1182/blood-2025-3445

Abstract Introduction The venetoclax-azacitidine (VEN-AZA) combination has become a standard treatment for AML in older patients (pts) or tho...

Exploring the spectrum of non-malignant complications in germline DDX41-associated hematologic disorders

Valeria Visconte, Serhan Unlu, Mark Orland et al. Nov 03, 2025 pp. 1445-1445 10.1182/blood-2025-1445

Abstract First discovered by our group in 2015 Cancer Cell. 2015 May 11;27(5):658-701 in an index family with history of MDS/AML, DDX41 is m...

VACARME : Analysis of humoral protection at baseline and after vaccination in patients with refractory/relapsed lymphoma and myeloma treated with CD19 and BCMA CAR T-cells.

Stéphanie Cordeil, Anne Conrad, Violaine Safar et al. Nov 03, 2025 pp. 713-713 10.1182/blood-2025-713

Abstract Introduction Introduction. CART-cell therapy targeting CD19 and B-cell maturation antigen (BCMA) has improved the prognosis of pati...

Macrophage CD38 overexpression drives primary platelet engraftment failure via paracrine suppression following allogeneic hematopoietic stem cell transplantation

Peng Wang, Jiaqian Qi, Meng Zhou et al. Nov 03, 2025 pp. 4202-4202 10.1182/blood-2025-4202

Abstract Background: Post-transplant thrombocytopenia (PT) is a severe complication following hematopoietic stem cell transplantation (HSCT)...

ACCELERATE: A platform protocol to investigate post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis in patients with hematologic malignancies undergoing mismatched unrelated donor peripheral blood stem cell transplantation

Sarah Smith, Heather Stefanski, Stephen Spellman et al. Nov 03, 2025 pp. 6035-6035 10.1182/blood-2025-6035

Abstract Background: Post-transplant cyclophosphamide (PTCy) has significantly improved the feasibility of mismatched unrelated donor (MMUD)...

Initial clinical data from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with large granular lymphocytic leukemia

Enrica Marchi, Tapan Kadia, Ryotaro Nakamura et al. Nov 03, 2025 pp. 777-777 10.1182/blood-2025-777

Abstract Introduction: Large granular lymphocytic leukemia (LGLL) is a chronic, incurable lymphoproliferative disorder of cytotoxic T (CD8)...

An update: Safety and efficacy of GPRC5D targeting CAR-T cell therapy in relapsed/refractory multiple myeloma patients

Shiqi Li, Yongwei Zheng, Zhongtao Yuan et al. Nov 03, 2025 pp. 5854-5854 10.1182/blood-2025-5854

Abstract Background: B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies have sho...

Continuous venetoclax for relapsed chronic lymphocytic leukemia (CLL) – characteristics and outcomes of long-term responders

Sean McKeague, Thomas Lew, LeiShong Lau et al. Nov 03, 2025 pp. 2130-2130 10.1182/blood-2025-2130

Abstract Aim: Venetoclax was initially approved for continuous use in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL), but t...

Low expression of TMSB10 in bone marrow in MDS patients with T cell large granular lymphocytic proliferation is associated with improved immune tolerance status of T cells and disease prognosis: Clinical data and single-cell sequencing analysis

Chenxiao Du, Shiqin Luo, Yuhui Zhang et al. Nov 03, 2025 pp. 5020-5020 10.1182/blood-2025-5020

Abstract Myelodysplastic syndromes/tumors (MDS) are a highly heterogeneous group of myeloid malignancies. It has been reported that 1.38%~20...

Real-world outcomes of immune checkpoint inhibitor rechallenge in patients with classical Hodgkin lymphoma

Giuseppe Maiocco, Yoshito Nishimura, Guneet Janda et al. Nov 03, 2025 pp. 5395-5395 10.1182/blood-2025-5395

Abstract Background: Immune checkpoint inhibitors (ICIs) have been established as standard of care for patients with classical Hodgkin lymph...

Decoding Transgene Silencing from Stably Maintained AAV Genomes in Human Liver: Epigenetic Insights to Guide Next-Generation Vector Design

Giulia Simini, Jenny McIntosh, Vincent Muczynski et al. Nov 03, 2025 pp. 4310-4310 10.1182/blood-2025-4310

Abstract Introduction Gene therapy offers transformative potential for monogenic disorders, with adeno-associated virus vectors (AAVs) servi...

Optimal therapy for pediatric B-ALL in first relapse: Comparative effectiveness of blinatumomab to hematopoietic cell transplantation versus CD19 CAR T cell therapy

Regina Myers, Yimei Li, Hongyan Liu et al. Nov 03, 2025 pp. 3339-3339 10.1182/blood-2025-3339

Abstract INTRODUCTION Outcomes for 1st relapse of pediatric B-lymphoblastic leukemia (B-ALL), especially high/intermediate-risk (HR/IR) relap...

Disparities in diagnosis and management of myelodysplastic syndromes in a brazilian cancer center: A comparison between public and private healthcare systems.

Arthur Gomes Oliveira Braga, Julia Curi Amarante, Humberto Villefort et al. Nov 03, 2025 pp. 2654-2654 10.1182/blood-2025-2654

Abstract Introduction: Disparities in access to healthcare services are well-documented in Brazil, where a mixed public-private system often...

Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial

Othman Al-Sawaf, Janina Stumpf, Can Zhang et al. Nov 03, 2025 pp. 1-1 10.1182/blood-2025-1

Abstract Introduction Current treatment for chronic lymphocytic leukemia (CLL) follows two seminal paradigms: continuous Bruton tyrosine kin...

Integrating patient and clinician perspectives to advance R/R CLL care: Results of a multi-pronged global initiative

Carmine Deluca, Michael Beyer, Marina Wanes et al. Nov 03, 2025 pp. 6428-6428 10.1182/blood-2025-6428

Abstract Background: The introduction of covalent BTK inhibitor (cBTKi) therapy and time-limited (TL) BCL2 inhibitor (BCL2i) regimens has es...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page